Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
June 04, 2021 09:00 ET
|
Constellation Pharmaceuticals , Inc.
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific expansion cohorts is...